News Related to Androgen Receptor Pathway Inhibitors

Related coverage linked through entity extraction aliases.

ESMO Guidelines Endorse Lutetium Therapy; New Data on PSMA Prediction, DOAC Safety

Jun 01, 2026

European guidelines now recommend lutetium-177 PSMA-617 for advanced prostate cancer, while a machine-learning model predicts treatment radiation dose. A study finds DOACs safe with modern prostate cancer drugs.

PARP inhibitors remain strongest in BRCA-mutant tumors as labels narrow

Apr 22, 2026

PARP inhibitors remain strongest in BRCA1/2-altered tumors as use beyond that group has been uneven. In June 2025, the FDA narrowed Zejula’s first-line ovarian maintenance indication to HRD-positive tumors only.